Bio­con on­col­o­gy spin­out Bicara se­cures its sec­ond nine-fig­ure fi­nanc­ing of the year

Bicara Ther­a­peu­tics, an im­munother­a­py start­up out of In­di­an bio­phar­ma gi­ant Bio­con, an­nounced a $165 mil­lion Se­ries C on Tues­day morn­ing.

The round fea­tured some blue …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER